Catalyst Pharmaceuticals (CPRX) Reaches $2.37 After 5.00% Up Move, TSS (TSSI) Sellers Increased By 3.06% Their Shorts

June 7, 2017 - By wolcottdaily

TSS INCORPORATED (OTCMKTS:TSSI) had an increase of 3.06% in short interest. TSSI’s SI was 101,000 shares in June as released by FINRA. Its up 3.06% from 98,000 shares previously. With 734,100 avg volume, 0 days are for TSS INCORPORATED (OTCMKTS:TSSI)’s short sellers to cover TSSI’s short positions. It is 0.00% or $0 reaching $0.182 per share. It is down 0.00% since June 7, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) is a huge mover today! About 139,362 shares traded. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has risen 267.48% since June 7, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.The move comes after 9 months positive chart setup for the $192.52 million company. It was reported on Jun, 7 by Barchart.com. We have $2.49 PT which if reached, will make NASDAQ:CPRX worth $9.63M more.

TSS, Inc. is a holding company. The Company provides various services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure, as well as integration services. The company has market cap of $2.73 million. The Firm operates through two divisions: facilities and systems integration. It has a 7.11 P/E ratio. The Company’s facilities segment is involved in the design, project management and maintenance of data center and mission-critical business operations.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $192.52 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.